Application of CCL5 in systemic lupus erythematosus lipid metabolism abnormality marker
By detecting the expression levels of CCL5 and its receptor CCR5 protein, combined with differential gene analysis and cytokine detection, the diagnosis problem of abnormal lipid metabolism in systemic lupus erythematosus was solved. It was found that low CCL5 expression levels are related to high risks, providing early recognition and prognosis Reliable markers for evaluation enhance the scientific and clinical value of disease prevention and treatment.
Patent Information
- Application Number
- CN202410952843.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-19
AI Technical Summary
There is a lack of reliable genetic markers in the prior art for early identification and prognostic evaluation of systemic lupus erythematosus, especially in the aspect of abnormal lipid metabolism, which makes it difficult to effectively diagnose and prevent disease progression.
CCL5 was used as a biomarker of lipid metabolism abnormality, and the expression level of CCL5 and its receptor CCR5 protein were detected, combined with differential gene analysis and cytokine detection, and the risk of lipid metabolism abnormality in patients with lupus erythematosus was evaluated.
It was found that patients with lupus erythematosus whose CCL5 expression levels were lower than those of the normal control group were at high risk. The significant reduction in CCL5 expression levels was linearly negatively correlated with the prevalence of abnormal lipid metabolism. CCL5 can be used as an independent risk factor to evaluate the risk of abnormal lipid metabolism. , has important scientific and clinical value.
Smart Images

Figure CN118980819A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of molecular biology, and in particular to the application of CCL5 in markers of abnormal lipid metabolism in systemic lupus erythematosus. Background Art
[0002] Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a protracted and recurrent course. Its main clinical features are the involvement of multiple organs and systems in the body, especially the deposition of multiple autoantibodies represented by antinuclear antibodies in the serum. SLE is a complex disease with multiple factors. Its etiology and pathogenesis have not yet been clarified. It is generally believed that its onset is related to genetics, immune abnormalities, sex hormones, environmental factors, drugs, etc. At present, the clinical diagnosis of this disease mainly relies on its main clinical manifestations and laboratory test indicators. Because the clinical manifestations of this disease are complex and changeable, if only a certain symptom or abnormal laboratory index is used as the standard, the primary disease is easily concealed and ignored, resulting in errors in the early diagnosis of the disease.
[0003] 30%-73% of adult patients with systemic lupus erythematosus (SLE) have dyslipidemia, which is generally manifested as increased chylomicrons (CM), triglycerides (TG), and very low-density lipoprotein-cholesterol (VLDL-C), and decreased high-density lipoprotein-cholesterol (HDL-C). Persistent hyperlipidemia can cause atherosclerosis (AS), leading to damage to multiple organs such as the heart, brain, and kidneys, affecting the occurrence, development, and prognosis of the disease itself. Understanding the characteristics of blood lipid metabolism in SLE patients will help prevent and treat the disease progression of SLE patients and improve the long-term survival rate of SLE patients.
[0004] Chemokines are a class of cytokines with chemotactic activity that play an important role in inflammatory responses. In-depth studies have found that chemokines and their receptors play an important role in nervous system diseases. Chemokine ligand 5 (CCL5), also known as RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted).
[0005] In the existing technology, there is still a lack of reliable genetic markers for early identification and prognosis assessment of abnormal lipid metabolism in systemic lupus erythematosus; research has now found that the expression level of CCL5 is correlated with whether lupus patients have abnormal lipid metabolism.
[0006] Therefore, the application of CCL5 in markers of abnormal lipid metabolism in systemic lupus erythematosus is proposed. Summary of the invention
[0007] The present invention provides application of CCL5 in markers of abnormal lipid metabolism in systemic lupus erythematosus.
[0008] Preferably, CCL5 is used as a biomarker of abnormal lipid metabolism in the preparation of a reagent for assessing the risk of abnormal lipid metabolism.
[0009] The present invention also provides the use of a CCL5 detection reagent in preparing a reagent for assessing the risk of disease caused by abnormal lipid metabolism. The CCL5 detection reagent is a reagent for detecting the expression level of CCL5 and its receptor CCR5 protein in a biological sample.
[0010] Preferably, the biological sample is CD4+T lymphocytes.
[0011] Preferably, the CCL5 detection reagent includes but is not limited to reagents for detecting the expression levels of CCL5 and its receptor CCR5 protein by immunohistochemistry (IHC), immunoblotting (WB), enzyme-linked immunosorbent assay (ELISA), IF, IP, and flow cytometry.
[0012] The present invention also provides a method for assessing the risk of dyslipidemia, comprising the following steps:
[0013] S1: Detecting the expression levels of serum CCL5 and its receptor CCR5 protein of the subject by using the detection reagent or the detection kit;
[0014] S2: Based on the protein expression levels of CCL5 and its receptor CCR5 detected in step S1, differential gene analysis is used to calculate the difference in the protein expression levels of CCL5 and its receptor CCR5 between lupus erythematosus patients with abnormal lipid metabolism and healthy samples, and to evaluate the correlation between the protein expression levels of CCL5 and its receptor CCR5 and the risk of abnormal lipid metabolism;
[0015] Furthermore, step S2 includes calculating log2FoldChange and P-value; comparing the lupus erythematosus lipid metabolism abnormality patient group with the healthy sample group through DESeq2, the CCL5 expression level of the lupus erythematosus lipid metabolism abnormality patient group is lower than that of the normal control group, and the calculated log2FoldChange value of CCL5 is -1.6622, which is between ±2, proving that the CCL5 expression level of lupus erythematosus patients with lipid metabolism abnormality is different from that of normal people and is significant; the P-value of 0.00000000195 is much smaller than 0.05, indicating that the significance level of the differentially expressed genes is very significant and the difference is statistically significant.
[0016] Preferably, cytokine detection and carotid artery ultrasound detection are performed on lupus erythematosus patients whose CCL5 expression level is lower than that of the normal control group; and healthy samples are tested as a control group at the same time;
[0017] The cytokine detection specifically includes VEGF, VEGF121, VEFD165 and PIGF, and the detection methods include but are not limited to human placental growth factor (PGF) ELISA kit, human vascular endothelial growth factor 165 (VEGF165) ELISA kit, human vascular endothelial growth factor 121 (VEGF121) ELISA kit, human vascular endothelial cell growth factor (VEGF) ELISA kit;
[0018] The carotid ultrasound examination specifically includes the left and right bilateral common carotid arteries (CCA), internal carotid arteries (ICA), and external carotid arteries (ECA);
[0019] Cytokine testing showed that lupus patients with too low CCL5 expression levels had vascular endothelial damage compared to the control group. At the same time, carotid artery ultrasound testing showed that lupus patients with CCL5 expression levels lower than those in the normal control group had vascular thickening. Both endothelial loss and vascular thickening are early manifestations of abnormal lipid metabolism. Through research, it was found that compared with normal people, lupus patients with too low CCL5 expression levels have a high risk of abnormal lipid metabolism.
[0020] The present invention has found through research that, compared with normal people, the serum CCL5 expression level of patients with lupus erythematosus lipid metabolism is significantly reduced, and the prevalence of lupus erythematosus lipid metabolism is linearly negatively correlated with the serum CCL5 expression level; the results of differential gene analysis show that the CCL5 expression level of lupus erythematosus patients with lipid metabolism disorders is significantly different from that of normal people; cytokine and carotid artery ultrasound control detection show that lupus erythematosus patients with CCL5 expression levels lower than those of normal people have a high risk of lipid metabolism disorders; that is, a lower CCL5 expression level is significantly correlated with the risk of lipid metabolism disorders, and the CCL5 expression level is an independent risk factor for lipid metabolism disorders, and can be used as a biomarker for lipid metabolism disorders to assess the risk of lipid metabolism disorders, which has important scientific and clinical value. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for describing the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative work.
[0022] Figure 1 This is a schematic diagram of the CCL5 monomer structure described in an embodiment of the present invention;
[0023] Figure 2This is the GO analysis enrichment map of CD4+T lymphocytes described in the embodiment of the present invention;
[0024] Figure 3 KEGG pathway analysis of CD4+T lymphocytes described in the embodiment of the present invention;
[0025] Figure 4 It is a volcano plot of differentially expressed genes in CD4+T lymphocytes described in the examples of the present invention. DETAILED DESCRIPTION
[0026] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0027] Example 1
[0028] like Figure 1-4 Shown
[0029] The chemokine (CC motif) ligand 5 described in this example is encoded by the CCL5 / RANTES gene, which is located on human chromosome 17q11.2-q12, contains 2 introns and 3 exons, and has a total length of 8,882 bp. The mRNA is 1,237 nt in length and encodes a protein composed of 91 amino acid residues. After the 23-amino acid leader sequence is removed, a mature protein containing 68 amino acid residues is obtained. The precursor of human CCL5 is a highly alkaline protein with a molecular weight of 8kD. There is no glycosylation site at the N-terminus, and its three-dimensional monomer structure is highly conserved. The nuclear magnetic resonance spectrum shows that the monomer of CCL5 contains a C-terminal helix, a three-stranded antiparallel sheet and two N-terminal short strands. The structure is shown in Figure 1 .
[0030] Example 2
[0031] Carotid artery ultrasound
[0032] The patient lies supine. The head is tilted to the opposite side with a pillow behind the neck. If the patient's condition does not allow, the patient can also sit or semi-sit. The probe is probed from the anterior position, lateral position, posterior lateral position, and super posterior lateral position.
[0033] The probe is moved from the base of the neck to the head for a lateral scan, showing the proximal, middle, distal ends of the common carotid artery, the carotid bifurcation, and the internal and external carotid arteries;
[0034] Measuring the inner diameter of the blood vessel: measuring the distance from the inner surface of the intima to the inner surface of the outer intima, based on the systolic period;
[0035] Carotid artery ultrasound examination was performed on lupus patients with low CCL5 expression levels and normal subjects;
[0036]
[0037] Table 1 Carotid artery ultrasound examination results of lupus erythematosus patients with low CCL5 expression level
[0038]
[0039]
[0040] Table 2 Carotid artery ultrasound test results of normal subjects as the control group
[0041] Through carotid artery ultrasound detection, it was found that according to the results in Table 1 and Table 2, compared with normal people, lupus erythematosus patients with lower CCL5 expression levels than the normal control group had thickened blood vessels. Therefore, lupus erythematosus patients with lower CCL5 expression levels than the normal control group have a high risk of abnormal lipid metabolism.
[0042] Example 3
[0043] Cytokine detection
[0044] Detection methods include, but are not limited to, human placental growth factor (PGF) ELISA kit, human vascular endothelial growth factor 165 (VEGF165) ELISA kit, human vascular endothelial growth factor 121 (VEGF121) ELISA kit, and human vascular endothelial cell growth factor (VEGF) ELISA kit;
[0045] The detection factor antibody is coated on the ELISA plate. During the experiment, the growth factor in the sample or standard will bind to the coated antibody, and the free components will be washed away. Biotinylated detection factor antibody and horseradish peroxidase-labeled avidin are added in sequence. The detection factor antibody binds to the detection factor bound to the coated antibody, and biotin specifically binds to avidin to form an immune complex, and the free components are washed away. Add a color substrate (TMB), TMB appears blue under the catalysis of horseradish peroxidase, and turns yellow after adding the stop solution. Use an ELISA instrument to measure the OD value at a wavelength of 450nm. The detection factor concentration is proportional to the OD450 value. The concentration of the detection factor in the sample is calculated by drawing a standard curve.
[0046] Cytokine detection was performed on lupus patients with low CCL5 expression levels and normal subjects;
[0047]
[0048] Table 3 Cytokine detection results of lupus erythematosus patients with low CCL5 expression level
[0049]
[0050] Table 4 Cytokine detection results of normal subjects as control group
[0051] Through cytokine detection, according to the results in Table 3 and Table 4, compared with normal people, lupus erythematosus patients with lower CCL5 expression levels than the normal control group have vascular endothelial damage. Therefore, lupus erythematosus patients with lower CCL5 expression levels than the normal control group have a high risk of abnormal lipid metabolism.
[0052] Example 4
[0053] Transcriptome analysis of CD4+ T lymphocytes in patients with lupus erythematosus
[0054] GO pathway analysis showed that the differentially expressed genes were significantly correlated with chemokine-related pathways, including chemokine receptor binding, chemokine-mediated signaling pathways, and various chemokine responses (e.g. Figure 2 shown);
[0055] KEGG pathway analysis showed that 2.5% of the differentially expressed genes screened were enriched in allogeneic transplant rejection, with one gene and a high correlation (e.g. Figure 3 shown).
[0056] The volcano plot of differentially expressed genes showed that the expression level of CCL5 in CD4+T lymphocytes of lupus patients was significantly different from that in CD4+T lymphocytes of healthy samples (e.g. Figure 4 shown).
[0057] In summary, lupus erythematosus patients with too low CCL5 expression levels in the present invention are at high risk of abnormal lipid metabolism, and CCL5 expression level is an independent risk factor for abnormal lipid metabolism. It can be used as a biomarker for abnormal lipid metabolism to assess the risk of abnormal lipid metabolism, and has important scientific and clinical value.
[0058] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.
[0059] The preferred embodiments of the present invention disclosed above are only used to help illustrate the present invention. The preferred embodiments do not describe all the details in detail, nor do they limit the invention to the specific implementation methods described. Obviously, many modifications and changes can be made according to the content of this specification. This specification selects and specifically describes these embodiments in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can understand and use the present invention well. The present invention is limited only by the claims and their full scope and equivalents.
Claims
1. Application of CCL5 as a marker of abnormal lipid metabolism in systemic lupus erythematosus.
2. Application of CCL5 as a biomarker of abnormal lipid metabolism in the preparation of reagents for assessing the risk of abnormal lipid metabolism.
3. Use of a CCL5 detection reagent in the preparation of a reagent for assessing the risk of developing abnormal lipid metabolism, wherein the CCL5 detection reagent is a reagent for detecting the expression levels of CCL5 and its receptor CCR5 protein in a biological sample.
4. The use according to claim 3, characterized in that: The biological sample is CD4+T lymphocytes.
5. The use according to claim 3, characterized in that: The CCL5 detection reagents include but are not limited to reagents for detecting the expression levels of CCL5 and its receptor CCR5 protein by immunohistochemistry, immunoblotting, enzyme-linked immunosorbent assay, IF, IP, and flow cytometry.
6. The use according to claim 1, characterized in that: Cytokine detection and carotid artery ultrasound were performed on lupus erythematosus patients whose CCL5 expression levels were lower than those of the normal control group; healthy samples were also tested as the control group.
7. The use according to claim 6, characterized in that: The cytokine detection specifically includes VEGF, VEGF121, VEFD165 and PIGF, and the detection methods include but are not limited to human placental growth factor enzyme-linked immunosorbent assay kit, human vascular endothelial growth factor 165 enzyme-linked immunosorbent assay kit, human vascular endothelial growth factor 121 enzyme-linked immunosorbent assay kit, and human vascular endothelial cell growth factor enzyme-linked immunosorbent assay kit.
8. The use according to claim 6, characterized in that: The carotid artery ultrasound detection specifically includes the left and right bilateral common carotid arteries, the internal carotid artery, and the carotid artery.
